United States-based Eli Lilly and Company (NYSE: LLY) announced yesterday that Taltz (ixekizumab) has met the primary and all major secondary endpoints up to week 12 in the Phase four IXORA-R study that evaluated the efficacy and safety of Taltz compared TREMFYA (guselkumab) in people living with moderate to severe plaque psoriasis (PsO).

The IXORA-R trial is the first completed head-to-head trial between an IL-17A inhibitor and an IL-23/p19 inhibitor using the Psoriasis Area Severity Index 100 score as the primary endpoint. At 12 weeks, the product has met the primary endpoint by showcasing superiority in the proportion of patients achieving complete skin clearance compared to TREMFYA as measured by PASI 100.

Andrew Blauvelt, MD, MBA, dermatologist and president of Oregon Medical Research Center in Portland, Oregon, said, 'Completely clear skin and rapid relief of symptoms are possible for many people living with moderate to severe plaque psoriasis, and should be two topics dermatologists discuss with their patients. Head-to-head data like these are important and will help inform individual treatment goal discussions between healthcare providers and their patients.'